Elucidating the specific pharmacological system of action (MOA) of naturally developing compounds may be challenging. Whilst Tarselli et al. (60) made the initial de novo artificial pathway to conolidine and showcased this Obviously happening compound effectively suppresses responses to the two chemically induced and inflammation-derived discomfort